Microbiome Therapeutics Market 2022 Development Trend, Chain Suppliers, Key Players Analysis and Forecast to 2025

New York, United States, 2022-Jun-03 — /EPR Network/ —

Microbiome Therapeutics Market is slated to grow on a decent note, i.e. witness a CAGR of 62.9% from 2018-2025, reaching US$ 897.3 Mn by the year 2018-2025. Workflows are getting streamlined due to increased connectivity and quicker internet. This is an era of medical IoT, which goes on to implement wearable devices and several other integrated applications for catering to healthcare needs. This would continue shortly as well.

According to the latest market report published by Persistence Market Research, titled ‘Microbiome Therapeutics Market Potential: Global Pipeline Analysis and Assessment 2018 – 2025’, the global microbiome therapeutics market is expected to exhibit an exponential CAGR of 62.9% during the forecast period 2018–2025.

Persistence Market Research estimates that the global market for microbiome therapeutics is expected to be valued at US$ 10.1 Mn in 2018 and is expected to reach US$ 897.3 Mn by 2025 end. Need for reliable, precise and fast treatment options for certain diseases, such as C. difficile infection (CDI), phenylketonuria, hepatic encephalopathy and multidrug resistant urinary tract infection creates a huge potential for the growth of the microbiome therapeutics market.

Get Free Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/7990

Breakthrough therapy designation and orphan drug approvals for microbiome therapeutics is expected to accelerate the launch of developmental drugs in the microbiome therapeutics market. A huge pipeline with over 120 candidates in different stages of development further creates the platform for potential growth of the microbiome therapeutics market.

Company Profiles:

• Microbiome Therapeutics Inc.
• SERES Therapeutics Inc.
• LNC Therapeutics Inc.
• Vedanta Biosciences Inc.
• Enterome SA
• Ferring B.V.
• ViThera Pharmaceuticals Inc.
• Second Genome Therapeutics
• Rebiotix
• Synlogic Inc.
• 4D Pharma Plc.
• Ritter Pharmaceuticals
• AvidBiotics
• Osel Inc.
• OxThera AB
• Evelo Biosciences
• AOBiome LLC
• Immuron Ltd.

Request for Methodology@ https://www.persistencemarketresearch.com/methodology/7990

More Than 120 Drugs Are in the Pipeline in the Global Microbiome Therapeutics Market

At present there are no marketed microbiome therapeutics in the global market; however, the first drug is expected to be launched in 2018. The global market is dominated by over 25 companies with more than 120 drugs in the pipeline at different stages of development. However, over 60% of these drugs are in the discovery or preclinical phase, where there is high uncertainty surrounding the success of these molecules to reach the clinical phase and being launched as a new drug molecule. Majority of the pipeline drugs are being developed for gastrointestinal disorders and contribute approximately 28.7% of the total pipeline products.

Research and development in the microbiome industry is prominently dependent on government funding and research grants. Formation of policies and provision of subsidy by various governments encourages research and development activities across various segments of the research including discovery and clinical research. Government initiatives in funding microbiome research is the preliminary factor driving revenue growth of global microbiome therapeutics market. For instance, the U.S. government had allocated US$ 1.6 Bn for microbiome R&D programs in 2016 & 2017.

Global Microbiome Therapeutics Market: Segmentation and Forecast

The market is segmented based on indication and region. On the basis of indication, the market has been segmented into type 2 diabetes, obesity, C. difficile infection and primary hyperoxyurea. C. difficile infection indication segment is expected to contribute the highest market share of over 34% by 2025 end. More number of product approvals for CDI is attributed to a high share of the C. difficile infection segment in the global market.

Human gut is home to over 100 Tn bacteria, containing thousands of different species. Long-term exposure to antibiotics causes dysbiosis in gut microbial composition, which leads to a variety of gastrointestinal disorders including CDI, ulcerative colitis, IBD, bacterial infection and even antibiotic associated diarrhea. Microbiome therapeutics however, present an excellent option for the treatment of CDI and other gastrointestinal disorders, as they are designed to naturally cure dysbiosis and bring the microbiome system back to normal functioning.

Access Full Report@ https://www.persistencemarketresearch.com/checkout/7990

Global Microbiome Therapeutics Market: Regional Forecast

On the basis of region, the market has been segmented into the U.S., Europe, Japan and Rest of the World (RoW). U.S. is estimated to contribute the highest share of over 44% by 2025 end, due to early launch of microbiome therapeutics and high penetration compared to other markets. The market in Japan is expected to witness delayed growth due to the complex regulatory pathways for new biological drugs. The microbiome therapeutics market in the rest of the world is expected to show gradual acceptance of “bug medicine”, Canada being the most lucrative among the rest of the world countries.

About us: Persistence Market Research

Contact us:

Persistence Market Research          
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com